Methylprednisolon, Lidocaine

PreclinicalSmall molecule

Methylprednisolon, Lidocaine is one of 40 small molecule programs targeting Shoulder pain. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Shoulder PainActive, not recruiting

Shoulder PainPreclinical

Active, not recruiting

Competition

Competitive Landscape

64 competitors in Shoulder Pain

#DrugCompanyPhaseTrials

Voltaren

Novartis

Approved

1 2

Savella

AbbVie

Approved

1 3

Prostigmin

Merck & Co.

Approved

1 4

Xylocaine

MMEDRx USA, Inc.

Approved

5 5

Medrol

Pfizer

Approved

—6

Naropin

FFresenius Kabi Oncology Ltd.

Approved

2 7

Kenalog

BBassett Healthcare

Approved

2 8

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 9

Versed

CConrado Roberto Hoffmann Filho

Approved

1 10

Marcaine

IInnocoll

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Shoulder pain1 trial

Hemiplegic Shoulder Pain Management Using Shoulder pRF and Corticosteroid Injection

Unknown status·SSatasairaala·N/A·NCT05563571·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Methylprednisolon, Lidocaine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methylprednisolon, Lidocaine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methylprednisolon, Lidocaine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Satasairaala company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSatasairaala

Methylprednisolon, Lidocaine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Shoulder pain1 trial

References

Drug Info

Quick Facts

Related News